Medgenics Inc Purchase of Common Stock by Chairman (6102V)

TIDMMEDG TIDMMEDU

RNS Number : 6102V

Medgenics Inc

16 December 2013

 
 Press Release   16 December 2013 
 

Medgenics Reports Open Market Purchase of Common Stock by Chairman of the Board

Medgenics, Inc. (AIM: MEDU, MEDG and NYSE MKT: MDGN), ("the Company"), the developer of Biopump(TM) , a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that on December 13, 2013, the Company was informed by Dr. Sol Barer, Medgenics' Chairman of the Board, that he purchased 20,000 shares of common stock on the open market on that day at an average price of $5.3711 per share.

Following this purchase, Dr. Barer now owns 112,000 shares of common stock, which represents approximately 0.6 per cent of the total issued shares of common stock. Dr. Barer, directly or through trusts for the benefit of Dr. Barer and his family, also has the right to purchase up to 1,315,000 shares of common stock pursuant to options previously granted (in aggregate Dr. Barer's shares of common stock and options represent 1,427,000 shares of common stock which represent approximately 7.7 per cent of the Company's total issued shares of common stock).

This announcement is being made pursuant to the London Stock Exchange's AIM Rules for Companies admitted to trading on the AIM market.

About Medgenics

Medgenics is developing and commercializing Biopump(TM), a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own tissue for the treatment of a range of chronic diseases including anemia, hepatitis, among others. For more information, please visit www.medgenics.com.

Contacts:

 
 Medgenics, Inc. 
  John Leaman, CFO 
  [e-mail] 
 
  LHA 
  Anne Marie Fields 
  212-838-3777 
  [e-mail] 
  @LHA_IR_PR 
 Abchurch Communications 
  Joanne Shears / Jamie Hooper 
  / Harriet Rae 
  [e-mail]      [phone] 
 Oriel Securities (NOMAD & Broker) 
  Jonathan Senior / Giles Balleny     [phone] 
 

-Ends-

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSEAEAKFEKDFFF